The Technical Analyst
Oramed Pharmaceuticals [ORMP]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Oramed Pharmaceuticals Price, Forecast, Insider, Ratings, Fundamentals & Signals
3.18% $2.27
America/New_York / 19 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 91.98 mill |
| EPS: | 0.140 |
| P/E: | 16.21 |
| Earnings Date: | May 09, 2024 |
| SharesOutstanding: | 40.52 mill |
| Avg Daily Volume: | 0.173 mill |
| RATING 2024-04-19 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Sell | |
| Return On Asset: | Neutral | |
| DE: | Strong Buy | |
| P/E: | Strong Sell | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 16.21 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 2.76x |
| Company: PE 16.21 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.319 (-85.97%) $-1.951 |
| Date: 2024-04-20 |
| Expected Trading Range (DAY) |
|---|
|
$ 2.07 - 2.47 ( +/- 8.63%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-17 | Reznick Yehuda | Buy | 29 800 | Common Stock |
| 2024-04-01 | Reznick Yehuda | Buy | 0 | |
| 2024-01-30 | Aghion Daniel | Buy | 3 750 | Common Stock |
| 2024-01-04 | Kidron Miriam | Buy | 295 500 | Common Stock |
| 2024-01-04 | Kidron Nadav | Buy | 329 000 | Common Stock |
| INSIDER POWER |
|---|
| 92.84 |
| Last 95 transactions |
| Buy: 3 987 636 | Sell: 392 701 |
Forecast:
16:00 - $2.27
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $2.27
Forecast 2: 16:00 - $2.27
Forecast 3: 16:00 - $2.27
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $2.27 (3.18% ) |
| Volume | 0.114 mill |
| Avg. Vol. | 0.173 mill |
| % of Avg. Vol | 65.52 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ORMP
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
ORMP
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York.
Last 10 Buy Signals
Latest Press Releases
2024-02-20 08:30:00 - Press Release
Oramed Letter To Shareholders
Initiating phase 3 oral insulin trial in the united states under a new protocol jv with chinese partner, htit scilex senior secured note peritech asset purchase & strategic out-licensing new york , feb. 20, 2024 /prnewswire/ -- oramed pharmaceuticals inc. (nasdaq: ormp) (tase: ormp) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today issued a letter to shareholders from its president and chief executive officer, nadav kidron. dear shareholders, i am pleased to share with you an update regarding oramed.
2023-09-21 18:11:00 - Press Release
Oramed Announces $101,875,000 Short-term Senior Secured Note Transaction With Scilex Holding Company
18-month loan with interest rate of sofr plus 8.5% oramed receives warrants to purchase up to 17 million shares of scilex common stock the senior secured note with scilex replaces oramed's previously announced stock purchase agreement and dip term loan with sorrento therapeutics new york , sept. 21, 2023 /prnewswire/ -- oramed pharmaceuticals inc. (nasdaq: ormp) (tase:ormp) today announced that on september 21, 2023, oramed and scilex holding company ("scilex") entered into a securities purchase agreement pursuant to which scilex issued a senior secured promissory note (the "note") to oramed.
2023-08-02 07:45:00 - Press Release
Oramed Signs Term Sheet With Htit To Create A Joint Venture To Advance Oral Drug Delivery Technology Globally
Jv will have global marketing rights to oral drug delivery technology htit to invest $60 million, oramed to invest $10 million into jv htit to provide a supply agreement for oral insulin capsule jv to advance registration of oral insulin in the united states and other countries new york , aug. 2, 2023 /prnewswire/ -- oramed pharmaceuticals inc. (nasdaq: ormp) (tase: ormp) (www.oramed.com) announced today that it has signed a non-binding term sheet with hefei tianhui biotech co., ltd. ("htit") to establish a joint venture ("jv") based on oramed's oral drug delivery technology.
2021-12-29 09:15:00 - Press Release
Mymd Pharmaceuticals Investment Company Oravax Medical Signs Cooperation And Purchase Agreement For Initial Pre-purchase Of 10 Million Doses Of Oral Covid-19 Vaccine To Be Commercialized In Southeast Asia
Baltimore--(business wire)--mymd pharmaceuticals, inc. (nasdaq: mymd) (“mymd” or “the company”), a clinical-stage pharmaceutical company committed to extending healthy lifespan, announced today that its investment company oravax medical inc. (“oravax”), partially owned with its majority partner oramed pharmaceuticals inc. (nasdaq: ormp) (“oramed”), has signed a cooperation and purchase agreement with vietnam-based tan thanh holdings investment joint stock company to pre-purchase oravax’s oral covid-19 vaccine, currently in development. the agreement is for an initial pre-order of 10 million doses of oral covid-19 vaccines from oravax and is comprised of milestone payments. the parties have agreed to negotiate potential follow-on orders that could be significant...
2021-11-18 09:15:00 - Press Release
Mymd Pharmaceuticals Investment Company Oravax Medical And Genomma Lab Announce Joint Venture To Develop And Commercialize Oral Covid-19 Vaccine In Mexico And Drive Business Development In Latin America
Baltimore--(business wire)--mymd pharmaceuticals, inc. (nasdaq: mymd) (“mymd” or “the company”), a clinical-stage pharmaceutical company committed to extending healthy lifespan, announced today that its investment company oravax medical inc. (“oravax”), partially owned with its majority partner oramed pharmaceuticals inc. (nasdaq: ormp) (“oramed”), has established a 50–50 joint venture with genomma lab internacional, s.a.b. de c.v. (bmv: labb), a leading pharmaceutical and personal care products company in latin america with an expanding international presence, to develop and commercialize oravax’s oral covid‑19 vaccine candidate in mexico. nadav kidron, oramed ceo and oravax chairman, and rodrigo herrera, genomma lab chairman, will hold a joint press event today, thursday, november 18, 2021 at 11:00 am est...
Latest News
2023-05-04 10:46:50 - PennyStocks
Best Penny Stocks To Buy Today? 4 To Watch Under $5
2023-01-12 11:50:45 - The Motley Fool
Why Oramed Pharmaceuticals Stock Is Crashing Today
The company's lead pipeline candidate is still being evaluated as a potential treatment for NASH after a major flop in treating type 2 diabetes.
2023-01-12 10:44:31 - InvestorPlace
Why Is Oramed (ORMP) Stock Down 75% Today?
Oramed (NASDAQ: ORMP ) stock is falling hard on Thursday after releasing data from a Phase 3 clinical trial. This clinical trial saw Oramed testing the efficiency of ORMD-0801 in patients with Type 2 Diabetes at 26 weeks against those taking a placebo.
2023-01-12 08:02:00 - Market Watch
Oramed's oral insulin pill fails; stock is down 72%
Shares of Oramed Pharmaceuticals Inc. ORMP, +5.78% plunged 72% in premarket trading on Thursday, the day after the company told investors its oral insulin medication did not meet the primary or secondary endpoints in a Phase 3 clinical trial. The randomized, double-blind, placebo-controlled trial compared Oramed's treatment to placebo to see if it improved glycemic control in patients with type 2 diabetes.
2022-12-07 03:49:24 - Seeking Alpha
Oramed: NASH Biotech Play With Added Bonus
Oramed achieved positive results from phase 2 study using ORMD-0801 for Type 2 Diabetes patients with NASH. Primary safety endpoint and secondary exploratory biomarker endpoints established proof of concept. Results from the phase 3 study using ORMD-0801 for the treatment of patients with Type 2 Diabetes are expected in January of 2023.
2022-09-21 05:52:39 - Seeking Alpha
Oramed: Oral Insulin For Type 2 Diabetes May Become A Reality
Results from Oramed Pharmaceuticals's first phase 3 study ORA-D-013-1, using ORMD-0801 for the treatment of patients with Type 2 Diabetes, is expected January 2023. Results from the ongoing Cohorts A and B, using Oravax for Covid-19, are going to be read out Q3 and Q4 of 2022 respectively.
2022-07-12 14:22:00 - The Motley Fool
Why Oramed Pharmaceuticals Stock Is On Fire Today
2022-07-08 17:56:00 - The Motley Fool
Why Oramed Pharmaceuticals Stock Rocketed Higher Today
2022-04-14 16:02:44 - Seeking Alpha
Oramed And Oral Insulin: Can This Small Company Really Do It?
Oramed is developing oral insulin in a phase 3 trial, data this year. Nobody has been able to deliver insulin orally in adequate quantity.
2021-12-29 06:14:05 - Market Watch
Oramed's Oravax sub signs pre-purchase agreement for 10 million oral COVID-19 vaccines with Tan Thanh
Oramed Pharmaceuticals Inc. ORMP, -11.40% said Wednesday its Oravax Medical subsidiary has signed an agreement with Vietnam-based Tan Thanh Holdings Investment Joint Stock Co. to pre-purchase 10 million doses of Oravax's oral COVID-19 vaccines in development. The drug maker's stock slipped 0.1% in premarket trading.